公开(公告)号：US20230365954A1

公开(公告)日：2023-11-16

申请号：US18201392

申请日：2023-05-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Brian Dwyer ,  Bohong Zhang ,  Jun Hu ,  Muthuraman Meiyappan ,  Thomas Miller ,  Paul McLean ,  Clark Pan

IPC: C12N9/40 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32

CPC classification number: C12N9/2465 ,  C12Y302/01022 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3219 ,  B01J20/3253 ,  B01J20/3255

Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., α-galactosidase A (α-Gal A), glucocerebrosidase (GCB), β-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.

公开(公告)号：US11685912B2

公开(公告)日：2023-06-27

申请号：US16978417

申请日：2019-03-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Brian Dwyer ,  Bohong Zhang ,  Jun Hu ,  Muthuraman Meiyappan ,  Thomas Miller ,  Paul McLean ,  Clark Pan

IPC: C12N9/40 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32

CPC classification number: C12N9/2465 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3219 ,  B01J20/3253 ,  B01J20/3255 ,  C12Y302/01022

Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., α-galactosidase A (α-Gal A), glucocerebrosidase (GCB), β-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.

公开(公告)号：US11660328B2

公开(公告)日：2023-05-30

申请号：US16761606

申请日：2018-11-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Clark Pan ,  Angela Norton ,  Bettina Strack-Logue ,  Clément Olivier

IPC: A61K38/26 ,  A61K47/68 ,  A61P1/00

CPC classification number: A61K38/26 ,  A61K47/6811 ,  A61P1/00

Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.